Skip to main content
Medicines for Malaria Venture
Developing antimalarials to save lives
Main navigation
Our work
Go back
Our work
MMV's pipeline of antimalarial drugs
Go back
MMV's pipeline of antimalarial drugs
Annual report 2022
Antimalarials for children
Antimalarials for pregnant women
Antimalarial drug resistance
Global health and societal change
Go back
Global health and societal change
Sustainable Development Goals
Gender equity
African manufacturing
Climate change and malaria
Research and development
Go back
Research and development
Target Product & Candidate Profiles
Frontrunner templates
Access to medicines
Go back
Access to medicines
Product registration maps
Antimalarial drug toolkits
Partnering & opportunities
Go back
Partnering & opportunities
Global partner network
Go back
Global partner network
Endemic country partners
Business model
Intellectual property rights
Opportunities
Go back
Opportunities
Requests for information or proposals
Newsroom
Malaria
Go back
Malaria
Malaria facts and statistics
Lifecycle of the malaria parasite
Species of Plasmodium parasites
History of antimalarial drugs
Malaria guidelines
Symptoms and treatments
About us
Go back
About us
About us
Go back
About us
Careers
FAQs
Diversity, Equity & Inclusion
Policies
Funding & expenditure
Donors
People & governance
Go back
People & governance
Staff bios
Board of Directors
North America Inc. Board
Access and Product Management Advisory Committee
Expert Scientific Advisory Committee
Global Safety Board
MMVOpen
Go back
MMVOpen
Open compounds
Go back
Open compounds
Call for antimalarial compounds
Global health priority box
Pandemic Response Box
Open dose and PK prediction tool
Open source drug discovery programme
Go back
Open source drug discovery programme
Open data repository
MMVOpen team
What are you looking for?
Home
Newsroom
News and Resources Search
MMV and ALMA
MMV and ALMA
MMV and ALMA
18 February 2011
Share
Dr David Reddy, CEO, MMV
